Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO)

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2014) M. Reck et al.   ANNALS OF ONCOLOGY

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

(2014) Roger Stupp et al.   LANCET ONCOLOGY

A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306)

(2012) L. Burt Nabors et al.   CANCER

Integrins as therapeutic targets

(2012) Simon L. Goodman et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Matched rabbit monoclonal antibodies against  v-series integrins reveal a novel  v 3-LIBS epitope, and permit routine staining of archival paraffin samples of human tumors

(2012) S. L. Goodman et al.   Biology Open

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study

(2011) Robert Pirker et al.   LANCET ONCOLOGY

Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma

(2010) Roger Stupp et al.   JOURNAL OF CLINICAL ONCOLOGY

Integrin signaling and lung cancer

(2010) Francesca Caccavari et al.   Cell Adhesion & Migration

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

(2009) Robert Pirker et al.   LANCET

Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme

(2008) David A. Reardon et al.   JOURNAL OF CLINICAL ONCOLOGY